GO:0008507 sodium:iodide symporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008507 sodium:iodide symporter activity describes the coupled transfer of iodide and sodium across a membrane, typically moving both ions into the cell.
• The protein responsible is SLC5A5 (NIS), a member of the SLC5 solute carrier family that is best known for concentrating iodide in the thyroid gland.
• NIS is an electrogenic secondary active transporter that uses the inward sodium gradient to drive iodide uptake against its concentration gradient.
• Loss or mislocalization of NIS causes radioactive iodine refractoriness in differentiated thyroid cancer, a major clinical problem.
• NIS is expressed in several extra-thyroidal tissues, including salivary glands, stomach, and lactating breast, which affects radioiodine biodistribution.
• NIS can be exploited as a reporter and therapeutic transgene in gene therapy and CAR-T cell engineering.
Description
GO:0008507 sodium:iodide symporter activity is a molecular function that enables the transfer of iodide and sodium ions across a membrane in a coupled manner. This activity is essential for the thyroid gland to accumulate iodide, a prerequisite for the synthesis of thyroid hormones. The protein that carries this activity, SLC5A5 (also called NIS), is a plasma membrane transporter that is central to thyroid physiology and to the clinical use of radioactive iodine. Because NIS-mediated iodide uptake is the first step in thyroid hormone biosynthesis and the basis for radioiodine imaging and therapy, understanding its mechanism, regulation, and tissue distribution is of broad biomedical importance. Researchers study this activity to dissect thyroid disease, to improve radioiodine-based cancer treatment, and to develop NIS as a reporter or therapeutic tool in gene and cell therapy.
sodium:iodide symporter activity At A Glance
| GO ID | GO:0008507 |
|---|---|
| GO term | sodium:iodide symporter activity |
| Ontology | molecular_function |
| Synonym | sodium/iodide symporter activity |
| Major function | Coupled transport of iodide and sodium across a membrane |
| Reaction | iodide(out) + Na+(out) = iodide(in) + Na+(in) |
| Representative protein | SLC5A5 (NIS) |
| Tissue context | Thyroid, salivary glands, stomach, lactating breast, and other extra-thyroidal sites |
| Clinical relevance | Radioiodine uptake, thyroid cancer refractoriness, gene therapy reporter |
What Is GO:0008507?
In simple terms, GO:0008507 describes a transporter activity that moves iodide and sodium together across a membrane, usually from outside the cell to inside. The official definition states that it enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: iodide(out) + Na+(out) = iodide(in) + Na+(in). This is a secondary active transport activity in which the inward sodium gradient provides the energy for iodide uptake.
Why Is sodium:iodide symporter activity Important in Cell Biology?
GO:0008507 is important because it is the molecular basis for iodide accumulation in the thyroid and several extra-thyroidal tissues, and it directly determines whether patients with thyroid cancer can benefit from radioactive iodine therapy. Loss of NIS expression or its mislocalization is a key mechanism of radioiodine refractoriness, making this activity a central target for understanding and overcoming treatment resistance. Beyond the thyroid, NIS expression in other tissues influences radioiodine biodistribution and can be harnessed for imaging and therapy. In addition, NIS is used as a reporter and therapeutic transgene in gene therapy and engineered cell therapies, which broadens its research and clinical value.
• Provides the first step in thyroid hormone synthesis by concentrating iodide in thyrocytes.
• Determines the efficacy of radioactive iodine imaging and therapy in thyroid cancer.
• Its loss or mislocalization underlies radioiodine refractoriness in differentiated thyroid cancer.
• Extra-thyroidal NIS expression affects radioiodine uptake in salivary glands, stomach, and breast.
• Serves as a reporter gene for non-invasive imaging of gene therapy vectors.
• Can be engineered into cells such as CAR-T cells to enable iodide-based imaging or therapy.
• Is regulated by cytokines and signaling pathways that influence thyroid autoimmunity and inflammation.
• Provides a model for studying secondary active transport and ion coupling.
• Its dimerization and structural dynamics are relevant to transporter function and regulation.
• Offers a target for experimental modulation in thyroid disease and cancer research.
Molecular Mechanism of sodium:iodide symporter activity
Sodium-coupled iodide transport
In simple terms: NIS uses the inward push of sodium to drag iodide into the cell.
The sodium:iodide symporter couples the movement of sodium and iodide across the membrane, with both ions typically moving into the cell. The inward sodium gradient, maintained by the sodium-potassium ATPase, provides the driving force for iodide uptake against its concentration gradient. This is a secondary active transport mechanism, and the reaction is electrogenic because sodium and iodide are co-transported.
Structural basis of transport
In simple terms: The shape of NIS allows it to bind sodium and iodide and change conformation to move them across.
Structural studies of the sodium:iodide symporter have provided insights into how the protein binds sodium and iodide and undergoes conformational changes during the transport cycle. These studies help explain the coupling stoichiometry and the molecular determinants of substrate specificity. The transporter is a member of the SLC5 family, and its architecture is consistent with other sodium-coupled transporters.
Dimerization and assembly
In simple terms: NIS proteins can pair up, and this pairing may affect how they work.
The sodium:iodide symporter can form dimers, and dimerization has been studied as a potential regulatory feature of the transporter. Dimerization may influence trafficking, stability, or activity of NIS at the plasma membrane. Understanding these assembly states is relevant to interpreting functional assays and to designing experiments that probe NIS regulation.
Regulation by signaling and cytokines
In simple terms: Signals from the body can turn NIS activity up or down.
Cytokines can modulate sodium:iodide symporter expression and function, linking inflammation to thyroid iodide handling. Altered signaling pathway activity and intracellular localization of NIS contribute to impaired iodide uptake in thyroid cancer. These regulatory layers affect both the amount of NIS at the membrane and its ability to transport iodide.
Tissue distribution and physiological roles
In simple terms: NIS is not only in the thyroid; it appears in several other tissues.
The sodium:iodide symporter is expressed in the thyroid and in extra-thyroidal tissues such as salivary glands, stomach, and lactating breast. This distribution explains why radioiodine is taken up by these tissues and why side effects can occur during therapy. The physiological roles of NIS in these tissues are an active area of research.
Key Genes Involved in GO:0008507 sodium:iodide symporter activity
The following genes and proteins are directly or functionally linked to sodium:iodide symporter activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC5A5 | Encodes the sodium:iodide symporter (NIS) that carries out GO:0008507 | Core transporter for iodide uptake; target for thyroid cancer and gene therapy studies |
| TSHR | Thyroid-stimulating hormone receptor that regulates thyroid function | Upstream regulator of NIS expression and thyroid iodide handling |
| PAX8 | Transcription factor important for thyroid development and gene expression | Regulates thyroid-specific genes including SLC5A5 |
| NKX2-1 | Thyroid transcription factor | Contributes to thyroid-specific expression programs including NIS |
| FOXE1 | Thyroid transcription factor | Involved in thyroid differentiation and NIS expression |
| SLC5A8 | Related sodium-coupled transporter | Provides comparative insight into SLC5 family transport mechanisms |
| ATP1A1 | Sodium-potassium ATPase subunit | Maintains the sodium gradient that drives NIS activity |
| TPO | Thyroid peroxidase | Works downstream of iodide uptake in thyroid hormone synthesis |
| TG | Thyroglobulin | Iodinated protein precursor of thyroid hormones |
| BRAF | Signaling kinase frequently mutated in thyroid cancer | Mutations can affect NIS expression and radioiodine refractoriness |
| RAS | Signaling GTPase mutated in thyroid cancer | Altered signaling contributes to loss of NIS function |
| PIK3CA | PI3K pathway component | Pathway activity changes can impair NIS expression and localization |
| PTEN | Tumor suppressor and PI3K pathway regulator | Loss can affect NIS expression and iodide uptake |
| IL1B | Proinflammatory cytokine | Modulates NIS expression and function in thyroid cells |
| IFNG | Proinflammatory cytokine | Affects NIS expression and thyroid autoimmunity |
| TNF | Proinflammatory cytokine | Influences NIS regulation and thyroid inflammation |
| SLC26A4 | Anion transporter (pendrin) | Contributes to iodide transport at the apical membrane of thyrocytes |
| CD3 | T cell receptor complex component | Used in CAR-T engineering where NIS is co-expressed as a reporter |
How Is sodium:iodide symporter activity Regulated?
Sodium:iodide symporter activity is regulated at multiple levels. Cytokines such as IL1B, IFNG, and TNF can modulate NIS expression and function, linking inflammation to altered iodide handling. In thyroid cancer, altered signaling pathway activity and changes in the intracellular localization of NIS contribute to impaired iodide uptake and radioiodine refractoriness. Transcriptional control by thyroid-specific transcription factors and post-translational trafficking events also influence the amount of functional NIS at the plasma membrane. These regulatory mechanisms are important for understanding why some thyroid tumors fail to concentrate iodide despite the presence of NIS protein.
sodium:iodide symporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC5A5 | Radioiodine-refractory thyroid cancer | Knockout or knockdown in thyroid cancer cell lines followed by iodide uptake assays |
| BRAF | Thyroid cancer with impaired NIS function | Point mutation knock-in of BRAF V600E in thyroid cells to study NIS repression |
| PIK3CA | Thyroid cancer with altered PI3K signaling | Overexpression or mutation models to assess NIS localization |
| IL1B | Thyroid inflammation and autoimmunity | Cytokine treatment of thyroid cells with NIS expression readouts |
| SLC5A5 | NIS-based gene therapy and imaging | Overexpression of NIS in non-thyroid cells or CAR-T cells for reporter assays |
Radioiodine-refractory thyroid cancer
Differentiated thyroid cancers often rely on sodium:iodide symporter activity for radioiodine uptake, but many tumors become refractory due to impaired NIS expression or mislocalization. Altered signaling pathways, including MAPK and PI3K pathways, contribute to this loss of function. Understanding these mechanisms is critical for developing strategies to restore iodide uptake and improve radioiodine therapy.
Thyroid autoimmunity and inflammation
Cytokines can modulate sodium:iodide symporter expression and activity, which may contribute to thyroid dysfunction in autoimmune and inflammatory conditions. This link between inflammation and iodide handling helps explain variability in thyroid function during immune-mediated disease.
Extra-thyroidal radioiodine uptake and side effects
NIS is expressed in extra-thyroidal tissues such as salivary glands, stomach, and lactating breast, which can lead to radioiodine uptake and associated side effects during therapy. This distribution is important for interpreting imaging results and managing patient care.
NIS as a therapeutic and reporter gene
Sodium:iodide symporter activity has been exploited in gene therapy approaches, including hepatocarcinoma models, where NIS expression enables iodide-based imaging and potential therapy. NIS co-expression in CAR-T cells has been studied for its effects on proliferation and cytotoxic activity in vitro, highlighting its use as a reporter and potential therapeutic module.
From sodium:iodide symporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC5A5 abolish iodide uptake? | SLC5A5 knockout cell line with iodide uptake assay |
| Does a specific mutation alter NIS transport activity? | Point-mutation knock-in of SLC5A5 in a thyroid cell line |
| Can NIS be used as a reporter in non-thyroid cells? | Knock-in of a tagged NIS or overexpression of NIS in a heterologous cell line |
| How does NIS dimerization affect function? | Tagged knock-in or overexpression of NIS variants followed by biochemical assays |
| Does cytokine signaling regulate NIS expression? | Overexpression or knockout of cytokine pathway components in thyroid cells |
| Can NIS co-expression improve CAR-T imaging? | Overexpression of NIS in CAR-T cells followed by functional assays |
How to Study the sodium:iodide symporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive iodide uptake | Functional NIS transport activity | Assessing iodide uptake in thyroid and engineered cells |
| Immunofluorescence | Subcellular localization of NIS | Detecting mislocalization in cancer cells |
| Cell surface biotinylation | Amount of NIS at the plasma membrane | Quantifying functional NIS at the cell surface |
| RNA-seq / qPCR | SLC5A5 mRNA expression | Evaluating transcriptional regulation of NIS |
| Western blot | NIS protein levels and modifications | Comparing expression across conditions |
| Structural biology (cryo-EM) | Three-dimensional structure of NIS | Understanding transport mechanism |
| Dimerization assays | NIS oligomeric state | Studying assembly and regulation |
| Reporter imaging | NIS-mediated iodide accumulation in vivo | Gene therapy and cell tracking |
Iodide uptake assays
Radioactive or fluorescent iodide uptake assays are used to measure sodium:iodide symporter activity directly in cells. These assays can be performed in thyroid cell lines or heterologous cells expressing NIS. They are essential for confirming whether a genetic perturbation affects transport function.
Protein localization and imaging
Immunofluorescence and cell surface biotinylation can assess whether NIS is correctly localized to the plasma membrane, which is critical for its activity. Imaging approaches using radioiodine or NIS reporters allow non-invasive assessment of NIS function in vivo. These methods help distinguish between loss of expression and mislocalization as causes of impaired iodide uptake.
Transcriptional and signaling analysis
RNA-seq and quantitative PCR can measure SLC5A5 mRNA levels, while pathway inhibitors and activators can probe signaling-dependent regulation. Such experiments help identify mechanisms of NIS repression in cancer and inflammation. Combining transcriptomic and functional data provides a more complete picture of NIS regulation.
Structural and biochemical studies
Structural biology and biochemical assays have been used to understand the transport cycle and dimerization of NIS. These approaches reveal how sodium and iodide are coordinated and how the protein changes conformation. They also inform the design of mutations that alter transport activity.
How CRISPR Can Be Used to Study GO:0008507 sodium:iodide symporter activity
Knockout
CRISPR knockout of SLC5A5 can abolish sodium:iodide symporter activity, providing a clean background to test iodide uptake and downstream effects. Knockout of regulatory genes such as BRAF or PTEN can reveal how signaling pathways control NIS expression and localization. These models are useful for validating causal roles of candidate genes in iodide handling.
Point Mutation
Point-mutation knock-in can be used to model specific SLC5A5 variants or cancer-associated mutations that alter NIS function. Such models help determine whether a mutation affects transport activity, substrate specificity, or protein stability. They are also valuable for studying mutations in signaling genes that impair NIS function.
Knock-in
Knock-in of tagged NIS or reporter cassettes allows tracking of NIS expression and localization in live cells and in vivo. This approach can be used to study NIS trafficking and to create imaging-competent cell models. Knock-in of NIS into non-thyroid cells can also create new tools for radioiodine-based assays.
Overexpression
Overexpression of SLC5A5 in heterologous cells or in CAR-T cells can confer sodium:iodide symporter activity for imaging or therapeutic purposes. Overexpression studies help assess whether NIS is sufficient to drive iodide uptake in a given cell type. They are also used to test the effects of NIS co-expression on cell proliferation and function.
How EDITGENE Supports sodium:iodide symporter activity Research
Researchers studying sodium:iodide symporter activity-related genes often need to determine whether a candidate gene is causally involved in iodide uptake, NIS localization, or radioiodine response. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations to test these hypotheses in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for sodium:iodide symporter activity research.
Frequently Asked Questions About sodium:iodide symporter activity
What is sodium:iodide symporter activity?
It is a molecular function (GO:0008507) that enables the coupled transfer of iodide and sodium across a membrane, typically moving both ions into the cell.
What genes are involved in sodium:iodide symporter activity?
The core gene is SLC5A5, which encodes NIS; other genes such as TSHR, PAX8, and signaling pathway components regulate its expression and function.
What is the role of SLC5A5 in the thyroid?
SLC5A5 encodes the sodium:iodide symporter that concentrates iodide in thyrocytes, the first step in thyroid hormone synthesis.
Why is sodium:iodide symporter activity important in thyroid cancer?
It determines whether thyroid cancer cells can take up radioactive iodine, and its loss or mislocalization causes radioiodine refractoriness.
Where else is the sodium:iodide symporter expressed?
It is expressed in extra-thyroidal tissues including salivary glands, stomach, and lactating breast, which affects radioiodine biodistribution.
How is sodium:iodide symporter activity regulated?
It is regulated by cytokines, signaling pathways, and intracellular trafficking, which can alter NIS expression and localization.
Can NIS be used as a reporter gene?
Yes, NIS has been used as a reporter and therapeutic transgene in gene therapy and cell engineering studies.
What experimental methods measure sodium:iodide symporter activity?
Radioactive iodide uptake assays, immunofluorescence, cell surface biotinylation, and RNA-seq are commonly used.
What diseases are linked to sodium:iodide symporter dysfunction?
Radioiodine-refractory thyroid cancer and thyroid inflammatory conditions are linked to impaired NIS function.
How can CRISPR help study sodium:iodide symporter activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise testing of genes that regulate NIS expression and function.
Conclusion
GO:0008507 sodium:iodide symporter activity is a central molecular function in thyroid physiology and a key determinant of radioiodine-based diagnosis and therapy. Its regulation by signaling pathways and cytokines, its structural mechanism, and its extra-thyroidal distribution are all active areas of research. CRISPR-based cell models provide powerful tools to dissect the genes and pathways that control this activity and to develop new strategies for thyroid cancer and gene therapy.
References
- 1. Baker CH et al.. 2004. The sodium-iodide symporter.. Curr Drug Targets Immune Endocr Metabol Disord 4(3):167-74 PMID: 15379719
- 2. Ravera S et al.. 2022. Structural insights into the mechanism of the sodium/iodide symporter.. Nature 612(7941):795-801 PMID: 36517601
- 3. Thompson RJ et al.. 2019. Dimerization of the Sodium/Iodide Symporter.. Thyroid 29(10):1485-1498 PMID: 31310151
- 4. Oh JM et al.. 2021. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.. Theranostics 11(13):6251-6277 PMID: 33995657
- 5. Gadisi RP et al.. 2025. The extra-thyroidal distribution of sodium iodide symporter.. Front Endocrinol (Lausanne) 16:1567405 PMID: 40678322
- 6. Schumm-Draeger PM. 2001. Sodium/iodide symporter (NIS) and cytokines.. Exp Clin Endocrinol Diabetes 109(1):32-4 PMID: 11573136
- 7. Haberkorn U. 2001. Gene therapy with sodium/iodide symporter in hepatocarcinoma.. Exp Clin Endocrinol Diabetes 109(1):60-2 PMID: 11573143
- 8. Tian C et al.. 2022. [Effects of sodium iodide symporter co-expression on proliferation and cytotoxic activity of chimeric antigen receptor T cells in vitro].. Nan Fang Yi Ke Da Xue Xue Bao 42(7):1062-1068 PMID: 35869771
